Alembic gets FDA nod for generic Bromday
Get great content like this right in your inbox.
Subscribe

Alembic Pharmaceuticals has received the Food and Drug Administration's approval for bromfenac ophthalmic solution 0.09%.
The product is the generic of Bausch & Lomb’s Bromday ophthalmic solution, 0.09%.
It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Bromfenac ophthalmic solution 0.09% has a market value of $6 million for the 12 months ending December 2018, according to IQVIA.
The product is the generic of Bausch & Lomb’s Bromday ophthalmic solution, 0.09%.
It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Bromfenac ophthalmic solution 0.09% has a market value of $6 million for the 12 months ending December 2018, according to IQVIA.